GlassScriptPhysician profile
Alina Basnet
NPI 1871914465
$4,645.08
in general payments reported to CMS, 2019-2025
32 companies · $2,973 in 2025
The $2,973 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $745 · 2022: $99.99 · 2023: $84.50 · 2024: $620 · 2025: $2,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,575 · Food and Beverage: $923 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,575.00 |
| Food and Beverage | $922.62 |
| Education | $179.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,691.28 | 2024-2025 | Tagrisso, Imfinzi, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $770.03 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $298.23 | 2022-2025 | Fotivda |
| Sirtex Medical INC | $122.98 | 2019 | |
| Merck Sharp & Dohme LLC | $98.26 | 2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $79.81 | 2025 | Opdivo |
| Janssen Biotech, INC. | $60.74 | 2025 | Rybrevant, Erleada, Akeega |
| Lilly USA, LLC | $47.23 | 2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $41.83 | 2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $40.20 | 2025 | Enhertu, Datroway |
| Puma Biotechnology, INC. | $39.73 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.73 | 2025 | Fruzaqla |
| Abbvie INC. | $33.45 | 2025 | |
| Pfizer INC. | $33.25 | 2025 | |
| Geron Corporation | $27.89 | 2025 | Rytelo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $26.86 | 2025 | |
| Array Biopharma INC | $24.96 | 2025 | Mektovi, Lorbrena, Braftovi |
| Stemline Therapeutics INC. | $24.61 | 2025 | Orserdu |
| Incyte Corporation | $24.38 | 2025 | Jakafi |
| Exelixis INC. | $23.73 | 2025 | Cabometyx |
| Tempus Ai, INC | $23.68 | 2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $23.31 | 2025 | Clonoseq |
| Beone Medicines USA, INC. | $21.57 | 2025 | Brukinsa |
| Eisai INC. | $17.08 | 2025 | |
| Celgene Corporation | $15.26 | 2025 | Opdivo |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alina Basnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.